Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-22T15:49:44.477Z Has data issue: false hasContentIssue false
  • English
  • Français

The use of benzodiazepines in schizophrenia: a review

Published online by Cambridge University Press:  16 April 2020

PM Llorca ,
MA Wolf  and
JP Estorges
PM Llorca
Affiliation:
Service de Psychiatrie d'Adultes, Hôpital Sainte-Marguerite, Bd de Ste-Marguerite, 13009Marseilles, France
MA Wolf
Affiliation:
Centre Hospitalier Robert Giffard, Québec, Canada
JP Estorges
Affiliation:
Service de Psychiatrie d'Adultes, Hôpital Sainte-Marguerite, Bd de Ste-Marguerite, 13009Marseilles, France
Get access

Summary

Benzodiazepines were first used in schizophrenia because of their anxiolytic properties. At high doses, or in association with neuroleptics, diazepam and estazolam also appears to exhibit an antihallucinatory effect, whereas alprazolam preferably acts on negative symptomatology due to its antidepressant properties.

Keywords

benzodiazepineschizophrenianegative symptoms
Type
Review article
Information
European Psychiatry , Volume 6 , Issue 5 , 1991 , pp. 217 - 222
Copyright
Copyright © Elsevier, Paris 1991

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abrams, RTaylor, MA (1978) A rating scale for emotional blunting. Am J Psychiatry 135, 226–229Google ScholarPubMed
Adan, FSiris, SG (1989) Trials of adjunctive alprazolam in “negative symptom” patients. Can /Psychiatry 34, 326–328CrossRefGoogle ScholarPubMed
Andreasen, NC (1983) The Scale for the Assessment of Negative Symptoms, SANS University of Iowa, Iowa City, IAGoogle Scholar
Andreasen, NC (1984) The Scale for the Assessment of Positive Symptoms, SANS University of Iowa, Iowa City, IAGoogle Scholar
Astrup, CVatten, L (1984) Effect of the benzodiazepine derivative estazolam in schizophrenia. Biol Psychiatry 19, 85–88Google Scholar
Beckmann, HHaas, J (1980) High dose diazepam in schizophrenia. Psychopharmacology 71, 79–82CrossRefGoogle Scholar
Bodkin, JA (1990) Emerging uses for high-potency benzodiazepines in psychotic disorders. J Clin Psychiatry 51 (suppl 5), 41–46Google ScholarPubMed
Bunney, WEHamburg, DA (1963) Methods for reliable longitudinal observations of behavior. Arch Gen Psychiatry 9, 280–294CrossRefGoogle ScholarPubMed
Colonna, LZann, M (1983) Usage des benzodiazépines dans les psychoses schizophréniques. Enceéphale 9, 279B–285BGoogle Scholar
Crow, TJ (1980) Positive and negative schizophrenic symptoms and the role of dopamine. Br J Psychiatry 137, 383–386CrossRefGoogle ScholarPubMed
Csernansky, JGLombrozo, LGulevich, GDHollister, LE (1984) Treatment of negative schizophrenic symptoms with alprazolam: a preliminary open-label study. J Clin Psychopharmacol 4, 349–352CrossRefGoogle ScholarPubMed
Csernansky, JGRiney, SJLombrozo, LOverall, JEHollister, LE (1988) Double-blind comparison of alprazolam, diazepam and placebo for the treatment of negative schizophrenic symptoms. Arch Gen Psychiatry 45, 655–659CrossRefGoogle ScholarPubMed
Dixon, LWeiden, PJFrances, AJSweeney, J (1989) Alprazolam intolerance in stable schizophrenic outpatients. Psychopharmacol Bull 25, 213–214Google ScholarPubMed
Douyon, RAngrist B, Peselow, ECooper, TRotrosen, J (1989) Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates. Am J Psychiatry 146, 231–234Google ScholarPubMed
Feighner, JPMeredith, CFrost, NR (1983) A double-blind comparison of alprazolam vs imipramine and placebo in the treatment of major depressive disorder. Acta Psychiatr Scand 68, 223–233CrossRefGoogle ScholarPubMed
Garbutt, JCVan Kammen, D (1983) The interaction between GABA and dopamine: implications for schizophrenia. Schizophr Bull 9, 336–353CrossRefGoogle Scholar
Gelder, MKolakowska, T (1979) Variability of response to neuroleptics in schizophrenia: clinical, pharmacologic and neuroendocrine correlates. Compr Psychiatry 20, 397–408CrossRefGoogle ScholarPubMed
Hankoff, LDRudorfer, LPaley, HM (1962) A reference study of ataraxies: a two-week double-blind outpatient evaluation. J New Drugs 2, 173–178CrossRefGoogle ScholarPubMed
Hommer, DWSkolnick, PPaul, SM (1987) The benzodiazepine/ GABA receptor complex and anxietyIn: Psychopharmacology: The Third Generation of Progress (Meltzer, HY ed) Raven Press, New York, 977–983Google Scholar
Hornykiewicz, O (1982) Brain catecholamines in schizophrenia: a good case for noradrenaline. Nature (Lond) 299, 484–486CrossRefGoogle ScholarPubMed
Jimmerson, DCVan Kammen, DPPost, RMDocherty, JPBunney, WE (1982) Diazepam in schizophrenia: a preliminary double-blind trial. Am J Psychiatry 139, 489–490Google Scholar
Jos, CJSchneider, RCannon, P (1985) Diazepam in the treatment of hallucinations. Am J Psychiatry 142, 1130–1131CrossRefGoogle ScholarPubMed
Kahn, CJPuertollano, MASchane, MDKlein, DF (1988) Adjunctive alprazolam for schizophrenia with panic anxiety: clinical observation and pathogenetic implications. Am J Psychiatry 145, 742–744Google ScholarPubMed
Karson, CNWeinberger, DRBigelow, LWyatt, RJ (1982) Clonazepam treatment of chronic schizophrenia: negative results in a double-blind, placebo-controlled trial. Am J Psychiatry 139, 1627–1628Google Scholar
Kellner, RWilson, RMMuldawer, MD (1979) Anxiety in schizophrenia: the response to chlordiazepoxide in an intensive design study. Arch Gen Psychiatry 32, 1246–1254CrossRefGoogle Scholar
Kirpatrick, BBuchanan, RWWaltrip, RWJauch, DCarpenter, WT (1989) Diazepam treatment of early symptoms of schizophrenic relapse. J Nerv Ment Dis 177, 52–53CrossRefGoogle Scholar
Lingjaerde, OEngstrand, EEllingsen, PStylo, DARobak, OH (1979) Antipsychotic effect of diazepam when given in addition to neuroleptics in chronic psychotic patients: a double-blind clinical trial. Curr Ther Res 26, 505–514Google Scholar
Lingjaerde, O (1982) Effect of the benzodiazepine derivative estazolam in patients with auditory hallucinations. Acta Psychiatr. Scand 65, 339–354CrossRefGoogle ScholarPubMed
Nestoros, JN (1980) Benzodiazepines in schizophrenia: a need for reassessment. Int Pharmacopsychiatry 15, 171–179CrossRefGoogle ScholarPubMed
Nestoros, JNSuranyi-Cadotte, BESpees, RCSchwartz, GNair, V (1982) Diazepam in high doses is effective in schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 6, 513–516CrossRefGoogle Scholar
Overall, JEGorham, DR (1962) The brief psychiatric rating scale. Psychol Rep 10, 799–812CrossRefGoogle Scholar
Pato, CNWolkowitz, OMRapaport, MSchulz, SCPickar, D (1989) Benzodiazepine augmentation of neuroleptic treatment in patients with schizophrenia. Psychopharmacol Bull 25, 263–266Google ScholarPubMed
Patris, M (1989) Prazepam et psychoses aigues. Psychologic Medicate 21, 141–151Google Scholar
Roberts, E (1972) An hypothesis suggesting that there is a defect in the GABA system in schizophrenia. Neurosci Res Progr Bull 10, 468–481Google Scholar
Ruskin, PAverbuch, IBelmaker, RH (1979) Benzodiazepines in chronic schizophrenia. Biol Psychiatry 14, 557–558Google ScholarPubMed
Smith, ME (1961) A clinical study of chlorpromazine and chlordizepoxide. Conn Med 25, 153–157Google Scholar
Vilkin, Ml (1964) Comparative chemotherapeutic trial in treatment of chronic borderline patients. Am J Psychiatry 120, 1004CrossRefGoogle ScholarPubMed
Wolkowitz, OMPickar, DDoran, ARBreier, ATarell, JPaul, SM (1986) Alprazolam augmentation neuroleptic treatment of the positive and negative symptoms of schizophrenia. Am J Psychiatry 143, 85–87Google Scholar
Wolkowitz, OMBreier, ADoran, AKelsoe, JLucas, PPaul, SMPickar, D (1988) Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients. Arch Gen Psychiatry 45, 664–671CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.